BGA
ACAD icon

Belmont Global Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Belmont Global Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$1.59M Sell
50,000
-100,000
-67% -$3.39M 1.51% 9
2016
Q2 		$4.87M Buy
+150,000
New +$5.02M 4.67% 6

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Belmont Global Advisors's ACAD Position: Q3 2016 in Review

Belmont Global Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q3 2016, closing a stake of 38,000 shares — an estimated $1.29M sold.

Belmont Global Advisors first reported a position in ACAD in Q1 2016 and held it in 2 quarters. The position peaked at $1.23M in Q2 2016. 232 funds tracked by Wall St. Rank hold ACAD as of Q3 2016.

  • Belmont Global Advisors reported no remaining Acadia Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Belmont Global Advisors sold 38,000 Acadia Pharmaceuticals shares in Q3 2016, an estimated $1.29M.
  • Belmont Global Advisors first reported a position in Acadia Pharmaceuticals in Q1 2016 and held it in 2 quarters.
  • Belmont Global Advisors's Acadia Pharmaceuticals position peaked at $1.23M in Q2 2016.
  • 232 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2016.

Based on Belmont Global Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.